Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oswaldo Castro

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
American Journal of Hematology|August 29, 2007
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell diseaseJames G Taylor, Diana Ackah, Crystal Cobb, et al.
American Journal of Hematology|June 1, 2010
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-upMartin H Steinberg, William F McCarthy, Oswaldo Castro, et al.
The Journal of Family Practice|October 3, 2007
Genetic screening for iron overload: No evidence of discrimination at 1 yearMark A Hall, James C Barton, Paul C Adams, et al.
British Journal of Haematology|February 24, 2010
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studiesRobyn J Barst, Kamal K Mubarak, Roberto F Machado, et al.
Blood|January 15, 2008
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemiaKenneth I Ataga, Wally R Smith, Laura M De Castro, et al.
Archives of Oral Biology|December 17, 2019
Effects of different pre-operative doses of dexamethasone on alveolar repair in ratsThiago Soares de Lima, Amanda de O P Ribeiro, Vinícius Bastos P Santos, et al.
European Journal of Haematology|February 14, 2009
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapyJane A Little, Kristine Partovi Hauser, Sabrina E Martyr, et al.
British Journal of Haematology|July 27, 2005
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertensionRoberto F Machado, Sabrina Martyr, Gregory J Kato, et al.
American Journal of Hematology|June 29, 2007
Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening studyChristine E McLaren, James C Barton, Victor R Gordeuk, et al.
Haematologica|August 4, 2006
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature reviewJane A Little, Vicki R McGowan, Gregory J Kato, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
American Journal of Hematology|August 29, 2007
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell diseaseJames G Taylor, Diana Ackah, Crystal Cobb, et al.
American Journal of Hematology|June 1, 2010
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-upMartin H Steinberg, William F McCarthy, Oswaldo Castro, et al.
The Journal of Family Practice|October 3, 2007
Genetic screening for iron overload: No evidence of discrimination at 1 yearMark A Hall, James C Barton, Paul C Adams, et al.
British Journal of Haematology|February 24, 2010
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studiesRobyn J Barst, Kamal K Mubarak, Roberto F Machado, et al.
Blood|January 15, 2008
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemiaKenneth I Ataga, Wally R Smith, Laura M De Castro, et al.
Archives of Oral Biology|December 17, 2019
Effects of different pre-operative doses of dexamethasone on alveolar repair in ratsThiago Soares de Lima, Amanda de O P Ribeiro, Vinícius Bastos P Santos, et al.
European Journal of Haematology|February 14, 2009
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapyJane A Little, Kristine Partovi Hauser, Sabrina E Martyr, et al.
British Journal of Haematology|July 27, 2005
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertensionRoberto F Machado, Sabrina Martyr, Gregory J Kato, et al.
American Journal of Hematology|June 29, 2007
Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening studyChristine E McLaren, James C Barton, Victor R Gordeuk, et al.
Haematologica|August 4, 2006
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature reviewJane A Little, Vicki R McGowan, Gregory J Kato, et al.
Pageof 5